West Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look For
West Pharmaceutical Services beat analysts' revenue expectations by 2% last quarter, reporting revenues of $698 million, flat year on year. It was a very strong quarter for the company, with a solid beat of analysts' EPS estimates and full-year revenue guidance beating analysts' expectations.
Is West Pharmaceutical Services a buy or sell going into earnings? Read our full analysis here, it's free.
This quarter, analysts are expecting West Pharmaceutical Services's revenue to grow 3.4% year on year to $725.9 million, a reversal from the 6.9% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.51 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. West Pharmaceutical Services has missed Wall Street's revenue estimates four times over the last two years.
Looking at West Pharmaceutical Services's peers in the life sciences tools & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 14.2%, beating analysts' expectations by 11.3%, and IQVIA reported revenues up 5.3%, topping estimates by 1.2%. Medpace traded up 54.6% following the results.
Read our full analysis of Medpace's results here and IQVIA's results here.
Investors in the life sciences tools & services segment have had steady hands going into earnings, with share prices flat over the last month. West Pharmaceutical Services is up 1.1% during the same time and is heading into earnings with an average analyst price target of $278.84 (compared to the current share price of $219).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
International Flavors and Fragrances beats quarterly revenue, profit estimates
(Reuters) -International Flavors and Fragrances topped Wall Street estimates for second-quarter revenue and profit on Tuesday, driven by resilient demand, higher prices and a shift to better-margin businesses. The company has streamlined its portfolio as choppy demand in some food and beauty markets forced its customers to hold leaner inventories. On Tuesday, the company, which disposed of its pharma solutions business earlier this year, said it would sell its soy crush, concentrates, and lecithin unit to U.S. grain trader and processor Bunge Global. IFF did not disclose financial terms but said the operations generated about $240 million in revenue in 2024. The company posted net sales of $2.76 billion for the quarter ended June 30, beating estimates of $2.70 billion, according to data compiled by LSEG. Its adjusted profit of $1.15 per share also topped expectations of $1.12. Advance purchases by packaged food and beauty companies looking to beat higher prices due to tariffs also boosted sales at IFF in the reported quarter. "We remain on track to deliver our 2025 commitments we outlined earlier this year, even as the operating environment has become more challenging," said CEO Erik Fyrwald. IFF's shares were up nearly 5% in extended trading. They have fallen about 16% so far this year. The New York-headquartered company maintained its annual sales and adjusted core profit targets. The company also said it authorized a new share buyback program with a total value of $500 million. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Long-Term Unemployment Rises In Worrying Sign For U.S. Labor Market
WASHINGTON – Signals of labor market weakness go beyond the headline numbers that prompted President Donald Trump to fire the government's head statistician last week. The jobs report released Friday showed a slowdown in hiring, a slight uptick in the national unemployment rate, and a few other clues that the economy is softening — including an increase in long-term unemployment. The number of people jobless for six months or more increased from 1.6 million to 1.8 million in July, representing 24% of the unemployed. It's the most people experiencing long-term joblessness since the end of 2021 and the highest percentage since February 2022, when the economy was still recovering from coronavirus lockdowns. Valerie Wilson, a labor economist at the liberal Economic Policy Institute, said the modest rise in long-term joblessness could reflect employers getting pickier about hiring as President Donald Trump's tariff regime changes the cost of doing business. 'People who have been unemployed for longer have clearly had some challenges in getting back into the labor market,' Wilson told HuffPost. 'I think that as things have softened, and employers are facing more uncertainty given the sort of chaotic nature of economic policy in this country, that it would be harder for those people to find new jobs.' The president's tariffs on goods imported from other countries are tantamount to a $1,219 tax increase on American households this year, according to an estimate by the conservative Tax Foundation. HuffPost readers: Dealing with long-term unemployment? Tell us about it – email arthur@ Please include your phone number if you're willing to be interviewed. Persistently high long-term joblessness was a hallmark of slow recovery from the Great Recession that officially ended in 2009. It disproportionately affected older workers, becoming a self-perpetuating problem as employers sought job applicants with minimal or no gaps on their resumes. Some economists worry another recession could be around the corner. The overall unemployment rate remained low in July, at just 4.2%, and the economy has continued to add jobs, albeit at a slower pace than previously estimated. Bureau of Labor Statistics data suggest the last three months were the weakest for job growth since the pandemic. Trump fired the BLS commissioner on Friday, claiming without evidence that the numbers were somehow 'rigged' to make him look bad. The labor force shrank slightly in July, helping hold down the unemployment rate even as the number of employed workers declined. Wilson noted the unemployment rate for Black Americans rose to 7.2%, up from a recent historical low of 4.8% in April 2023. 'Over the last two months, we're seeing the black unemployment rate pick up, which is another one that as that starts to rise, we start to look for signals of a broader slowing in the economy,' Wilson said.
Yahoo
16 minutes ago
- Yahoo
Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations
DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea's global investor relations strategy, serving as a key liaison to the investment community. 'Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter,' said McConnell. 'She brings not only deep capital markets expertise but also integrity, insight and a strong track record of supporting strategic transformation and growth. We're excited to welcome her to the team. I also would like to express my sincere appreciation to Hima Inguva, who has led Fortrea's Investor Relations since our founding as a company. We wish her every success in her next chapter.' Krumme brings more than three decades of investor relations and capital markets experience to Fortrea, with expertise across the CRO, life sciences and healthcare sectors. She previously served as head of investor relations at PPD, a leading CRO acquired by Thermo Fisher Scientific, where she worked alongside Fortrea's CEO Anshul Thakral; Galderma, a global dermatology company; and Nuance Communications, a provider of healthcare AI solutions acquired by Microsoft. Most recently, she was senior vice president, head of investor relations and corporate communications at Bitfarms, a global energy and compute infrastructure company. Earlier in her career, she led investor relations at Luxoft, acquired by DXC Technology, and NCR Corporation, and held roles as an equity research analyst at Sandler O'Neill & Partners and in corporate finance at Prudential Securities and Kidder, Peabody International in London. 'I'm excited to join Fortrea at such a pivotal moment in its evolution as an independent, pure-play CRO,' said Krumme. 'I look forward to working with the leadership team to articulate Fortrea's vision and value proposition to the investment community as we deliver differentiated solutions to our customers and generate long-term value for shareholders.' About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at and follow us on LinkedIn and X (formerly Twitter). Fortrea Contacts: Tracy Krumme (Investors) – 984-385-6707, Inguva (Investors) – 877-495-0816, Sue Zaranek (Media) – 919-943-5422, media@ Kate Dillon (Media) – 646-818-9115, kdillon@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
